{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T09:17:35Z","timestamp":1776763055074,"version":"3.51.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Growing prevalence of multidrug-resistant\/Rifampicin-resistant tuberculosis (MDR\/RR-TB; resistance to Isoniazid and Rifampicin\/Isolated resistance to Rifampicin) is putting in jeopardy the WHO End TB strategy. This study aimed to identify factors contributing to the high prevalence of MDR\/RR-TB in Khabarovsk krai region of Russia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cross-sectional retrospective study was conducted, analyzing clinical, demographic, and drug susceptibility testing data on 1440 patients. As a source of raw data, the national electronic TB surveillance system was used. Anonymous data was collected on every patient diagnosed with TB in all healthcare facilities of the region from January 2018 to December 2019. Only patients with proven excretion of <jats:italic>m. tuberculosis<\/jats:italic> were included in the study. Factors associated with MDR\/RR-TB were identified through logistic regression analysis, in conjunction with in-depth interviews with eight patients, five healthcare managers and five doctors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Findings<\/jats:title>\n                <jats:p>2661 patients were identified with TB, 1440 were incorporated in the study based on inclusion criteria. Of these, 618 (42.9%) were identified with MDR\/RR-TB. Patients with a history of imprisonment were 16.53 times (95% CI 5.37 to 50.88,) more likely to have MDR\/RR-TB, whereas re-treatment patients were 2.82 times (95% CI 2.16 to 3.66) more likely to have MDR\/RR-TB. Other influencing factors included presence of disability (AOR is 2.32, 95% CI 1.38 to 3.89), cavitary disease (AOR is 1.76, 95% CI 1.37 to 2.25), and retirement status (AOR 0.65, 95% CI 0.43 to 0.98, p\u2009=\u20090.042). Poor patient knowledge and understanding of the disease, progressive weariness of prolonged TB treatment, and inability hospitalize infectious patients without their consent were perceived by the interviewees as major influencing factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Incarceration and treatment history, regardless of outcome, were identified as major factors influencing MDR\/RR-TB prevalence. It is essential for the TB care system to eliminate legal loopholes, which deprive doctors of means to enforce quarantine procedures and epidemiological surveillance on infected patients, former and current inmates. Increasing people\u2019s awareness of TB, early detection and appropriate treatment of patients with TB are needed for successfully combating MDR\/RR-TB.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07598-7","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T16:08:22Z","timestamp":1657728502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Factors contributing to the high prevalence of multidrug-resistance\/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia"],"prefix":"10.1186","volume":"22","author":[{"given":"Ilia","family":"Bykov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Dyachenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Ratmanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qunhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"7598_CR1","doi-asserted-by":"publisher","unstructured":"Caminero Luna JA, P\u00e9rez Mendoza G, Rodr\u00edguez de Castro F. Multi-drug resistant tuberculosis, ten years later. Med Clin (Barc). 2021;156(8):393\u2013401. https:\/\/doi.org\/10.1016\/j.medcli.2020.08.018.","DOI":"10.1016\/j.medcli.2020.08.018"},{"key":"7598_CR2","doi-asserted-by":"publisher","first-page":"A174","DOI":"10.1136\/thorax-2020-BTSabstracts.302","volume":"76","author":"M Park","year":"2021","unstructured":"Park M, Padayachee Y, Ryan L, et al. P157\u2005Multidrug resistant tuberculosis\u2014patients\u2019 perspective and experiences in a London TB centre. 2 Thorax. 2021;76:A174. https:\/\/doi.org\/10.1136\/thorax-2020-BTSabstracts.302.","journal-title":"2 Thorax."},{"key":"7598_CR3","doi-asserted-by":"publisher","unstructured":"Pedrazzoli, D. The Economic Burden of Tuberculosis and the Mitigation Effect of Social Protection: A Population-Based Study in Ghana. PhD thesis, London School of Hygiene & Tropical Medicine. 2020. https:\/\/doi.org\/10.17037\/PUBS.04658405","DOI":"10.17037\/PUBS.04658405"},{"key":"7598_CR4","unstructured":"Global tuberculosis report 2021. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2021. Accessed 7 May 2022."},{"key":"7598_CR5","unstructured":"Global tuberculosis report 2019: executive summary. Geneva: World Health Organization; 2019. https:\/\/www.who.int\/publications\/i\/item\/9789241565714. Accessed 7 May 2022."},{"issue":"15","key":"7598_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.33667\/2078-5631-2019-1-15(390)-7-18","volume":"1","author":"MV Shilova","year":"2019","unstructured":"Shilova MV. Tuberculosis in population of Russian Federation. Med Alpha. 2019;1(15):7\u201318. https:\/\/doi.org\/10.33667\/2078-5631-2019-1-15(390)-7-18.","journal-title":"Med Alpha."},{"issue":"4","key":"7598_CR7","first-page":"402","volume":"10","author":"SS Shin","year":"2006","unstructured":"Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Andreev YG, Keshavjee S, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberculosis Lung Dis. 2006;10(4):402\u20138.","journal-title":"Int J Tuberculosis Lung Dis."},{"key":"7598_CR8","unstructured":"Bogorodskaya E.M., Smerdin S.V., Sterlikov S.A. Organizational aspects of treatment of patients with tuberculosis in modern socio-economic conditions. Moscow. 2011; 50\u201375. Russian."},{"issue":"37","key":"7598_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017027","volume":"98","author":"L Chang","year":"2019","unstructured":"Chang L, Su Y, Zhu R, Duan Z. Mapping international collaboration in tuberculosis research from 1998 to 2017: a scientometric study. Medicine (Baltimore). 2019;98(37): e17027. https:\/\/doi.org\/10.1097\/MD.0000000000017027.","journal-title":"Medicine (Baltimore)"},{"key":"7598_CR10","unstructured":"WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/332397\/9789240007048-eng.pdf. Accessed 7 May 2022."},{"key":"7598_CR11","doi-asserted-by":"publisher","unstructured":"Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, Members of the Global Tuberculosis Network; et al. MDR\/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis. 2020. Doi: https:\/\/doi.org\/10.1016\/j.ijid.2020.01.042.","DOI":"10.1016\/j.ijid.2020.01.042"},{"issue":"7","key":"7598_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236250","volume":"15","author":"C Tenzin","year":"2020","unstructured":"Tenzin C, Chansatitporn N, Dendup T, Dorji T, Lhazeen K, Tshering D, Pelzang T. Factors associated with multidrug-resistant tuberculosis (MDR-TB) in Bhutan: a nationwide case-control study. PLoS ONE. 2020;15(7): e0236250. https:\/\/doi.org\/10.1371\/journal.pone.0236250.","journal-title":"PLoS ONE"},{"issue":"1","key":"7598_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12879-018-3167-9","volume":"18","author":"B Demile","year":"2018","unstructured":"Demile B, Zenebu A, Shewaye H, Xia S, Guadie A. Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia. BMC Infect Dis. 2018;18(1):249. https:\/\/doi.org\/10.1186\/s12879-018-3167-9.","journal-title":"BMC Infect Dis"},{"key":"7598_CR14","doi-asserted-by":"publisher","DOI":"10.22159\/ijap.2019.v11s6.33539","author":"CM Rumende","year":"2018","unstructured":"Rumende CM. Risk factors for multidrug-resistant tuberculosis. Acta Med Indon. 2018. https:\/\/doi.org\/10.22159\/ijap.2019.v11s6.33539.","journal-title":"Acta Med Indon."},{"key":"7598_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2018.10.004","author":"IS Pradipta","year":"2018","unstructured":"Pradipta IS, et al. Risk factors of multidrug-resistant tuberculosis: a global systematic review and meta-analysis. J Infect. 2018. https:\/\/doi.org\/10.1016\/j.jinf.2018.10.004.","journal-title":"J Infect"},{"key":"7598_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225361","author":"Z Lu","year":"2019","unstructured":"Lu Z, Jiang W, Zhang J, Lynn HS, Chen Y, Zhang S, et al. Drug resistance and epidemiology characteristics of multidrug-resistant tuberculosis patients in 17 provinces of China. PLoS ONE. 2019. https:\/\/doi.org\/10.1371\/journal.pone.0225361.","journal-title":"PLoS ONE"},{"issue":"3","key":"7598_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.5588\/pha.21.0007","volume":"11","author":"KC McNabb","year":"2021","unstructured":"McNabb KC, Bergman A, Farley JE. Risk factors for poor engagement in drug-resistant TB care in South Africa: a systematic review. Public Health Action. 2021;11(3):139\u201345. https:\/\/doi.org\/10.5588\/pha.21.0007.","journal-title":"Public Health Action"},{"issue":"3","key":"7598_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3201\/eid2203.151788","volume":"22","author":"TE Tupasi","year":"2016","unstructured":"Tupasi TE, Garfin AM, Kurbatova EV, Mangan JM, Orillaza-Chi R, Naval LC, Balane GI, Basilio R, Golubkov A, Joson ES, Lew WJ, Lofranco V, Mantala M, Pancho S, Sarol JN Jr. Factors associated with loss to follow-up during treatment for multidrug-resistant tuberculosis, the Philippines, 2012\u20132014. Emerg Infect Dis. 2016;22(3):491\u2013502. https:\/\/doi.org\/10.3201\/eid2203.151788.","journal-title":"Emerg Infect Dis"},{"key":"7598_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.12737\/article_59e859b2681e23.53680380","volume":"2","author":"VA Astafyev","year":"2018","unstructured":"Astafyev VA, Ogarkov OB, Zhdanov SN, Kravchenko AF, Vinokurova MK, Chemezova NN, Zorkaltseva EYu, Shugayeva SN, Savilov ED. Tuberculosis features in federal districts of the Russian Federation. Acta Biomed Sci. 2018;2:168\u201373. https:\/\/doi.org\/10.12737\/article_59e859b2681e23.53680380.","journal-title":"Acta Biomed Sci."},{"issue":"9","key":"7598_CR20","first-page":"866","volume":"7","author":"ME Kimerling","year":"2003","unstructured":"Kimerling ME, Slavuckij A, Chavers S, Peremtin GG, Tonkel T, Sirotkina O, Golubchikova V, Baddeley A. The risk of MDR-TB and polyresistant tuberculosis among the civilian population of Tomsk city, Siberia, 1999. Int J Tuberc Lung Dis. 2003;7(9):866\u201372.","journal-title":"Int J Tuberc Lung Dis"},{"key":"7598_CR21","first-page":"17","volume":"1","author":"IS Gelberg","year":"2015","unstructured":"Gelberg IS, Wolf SB, Alekso EN, et al. Risk factors of multidrug-resistant tuberculosis development. Kursk Sci Pract Bull. 2015;1:17\u201322 (Russian).","journal-title":"Kursk Sci Pract Bull."},{"issue":"1","key":"7598_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.36422\/23076348-2020-8-1-6-13","volume":"8","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zagdyn Z, Pavlova M, Archakova L, Sokolovich E, Yablonskiy P, et al. TB and HIV in the Russian Federation: Risk Factors of MDR-TB in HIV-infected Patients. Med All. 2020;8(1):6\u201313. https:\/\/doi.org\/10.36422\/23076348-2020-8-1-6-13.","journal-title":"Med All"},{"issue":"11","key":"7598_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.21292\/2075-1230-2020-98-11-6-11","volume":"98","author":"VV Testov","year":"2020","unstructured":"Testov VV, Sterlikov SA, Vasilyeva IA, Sidorova IA, Mikhaylova YV, et al. Federal Register of TB Cases as a tool for monitoring the impact of COVID-19 pandemic response activities on the TB care system. Tuberculosis Lung Dis. 2020;98(11):6\u201311. https:\/\/doi.org\/10.21292\/2075-1230-2020-98-11-6-11.","journal-title":"Tuberculosis Lung Dis."},{"key":"7598_CR24","unstructured":"Guidelines for surveillance of drug resistance in tuberculosis 5th editiom. Geneva: World Health Organization; 2020. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/174897\/9789241549134_eng.pdf?sequence=1. Accessed 7 May 2022."},{"issue":"11","key":"7598_CR25","first-page":"657","volume":"73","author":"H Ohno","year":"1998","unstructured":"Ohno H, Koga H, Kohno S. Multidrug-resistant tuberculosis. 2. Mechanisms of drug-resistance in Mycobacterium tuberculosis\u2013genetic mechanisms of drug-resistance. Kekkaku. 1998;73(11):657\u201363 (Japanese).","journal-title":"Kekkaku"},{"key":"7598_CR26","doi-asserted-by":"publisher","unstructured":"Harrell FE. Binary logistic regression: In: Regression modeling strategies. Cham: Springer. 2015. https:\/\/doi.org\/10.1007\/978-3-319-19425-7_10","DOI":"10.1007\/978-3-319-19425-7_10"},{"key":"7598_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00062-6","author":"TM Walker","year":"2015","unstructured":"Walker TM, Kohl TA, Omar SV, Hedge J, Elias CDO, Bradley P, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis. 2015. https:\/\/doi.org\/10.1016\/S1473-3099(15)00062-6.","journal-title":"Lancet Infect Dis"},{"key":"7598_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032976","author":"Y Pang","year":"2012","unstructured":"Pang Y, Zhou Y, Zhao B, Liu G, Jiang G, Xia H, Zhao YL, et al. Spoligotyping and drug resistance analysis of Mycobacterium tuberculosis strains from national survey in China. PLoS ONE. 2012. https:\/\/doi.org\/10.1371\/journal.pone.0032976.","journal-title":"PLoS ONE"},{"key":"7598_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/MRA.00352-21","author":"N Zainal Abidin","year":"2021","unstructured":"Zainal Abidin N, Noorizhab MNF, Teh LK, Lim WF, MohdNoordin N, Aziz ZA, Abu Bakar Z, Ismail AI, MohdNor N, Salleh MZ. Draft genome sequences of local clinical isolates of drug-resistant and drug-sensitive mycobacterium tuberculosis. Microbiol Resour Announc. 2021. https:\/\/doi.org\/10.1128\/MRA.00352-21.","journal-title":"Microbiol Resour Announc."},{"issue":"6","key":"7598_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.5588\/ijtld.21.0033","volume":"25","author":"E Roycroft","year":"2021","unstructured":"Roycroft E, Fitzgibbon MM, Kelly DM, Scully M, McLaughlin AM, Flanagan PR, Keane J, et al. The largest prison outbreak of TB in Western Europe investigated using whole-genome sequencing. Int J Tuberc Lung Dis. 2021;25(6):491\u20137. https:\/\/doi.org\/10.5588\/ijtld.21.0033.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"7598_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-021-11271-0","volume":"21","author":"S Gatechompol","year":"2021","unstructured":"Gatechompol S, Harnpariphan W, Supanan R, Suwanpimolkul G, Sophonphan J, Ubolyam S, Kawkitinarong K, et al. Prevalence of latent tuberculosis infection and feasibility of TB preventive therapy among Thai prisoners: a cross-sectional study. BMC Public Health. 2021;21(1):1\u20138. https:\/\/doi.org\/10.1186\/s12889-021-11271-0.","journal-title":"BMC Public Health"},{"key":"7598_CR32","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S0140-6736(16)30466-4","volume":"388","author":"K Dolan","year":"2016","unstructured":"Dolan K, Wirtz AL, Moazen B, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388:1089\u2013102. https:\/\/doi.org\/10.1016\/S0140-6736(16)30466-4.","journal-title":"Lancet"},{"key":"7598_CR33","unstructured":"Highest to Lowest\u2014Prison Population Total. Birkbeck University of London; 2021. https:\/\/www.prisonstudies.org\/highest-to-lowest\/prison-population-total. Accessed 7 May 2022."},{"issue":"3","key":"7598_CR34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ijid.2008.07.015","volume":"13","author":"W Jakubowiak","year":"2009","unstructured":"Jakubowiak W, Bogorodskaya E, Borisov S, Danilova I, Kourbatova E. Treatment interruptions and duration associated with default among new patients with tuberculosis in six regions of Russia. Int J Infect Dis. 2009;13(3):362\u20138. https:\/\/doi.org\/10.1016\/j.ijid.2008.07.015.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"7598_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2471\/BLT.12.104588","volume":"91","author":"A Skrahina","year":"2013","unstructured":"Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, Hoffner S, Rusovich V, Dadu A, de Colombani P, Dara M, van Gemert W, Zignol M. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ. 2013;91(1):36\u201345. https:\/\/doi.org\/10.2471\/BLT.12.104588.","journal-title":"Bull World Health Organ"},{"issue":"4","key":"7598_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.5588\/pha.14.0069","volume":"4","author":"V Rusovich","year":"2014","unstructured":"Rusovich V, Kumar AM, Skrahina A, et al. High time to use rapid tests to detect multidrug resistance in sputum smear-negative tuberculosis in Belarus. Public Health Action. 2014;4(4):243\u20138. https:\/\/doi.org\/10.5588\/pha.14.0069.","journal-title":"Public Health Action."},{"issue":"7","key":"7598_CR37","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/thoraxjnl-2011-200018","volume":"67","author":"L Liang","year":"2012","unstructured":"Liang L, Wu Q, Gao L, Hao Y, Liu C, Xie Y, Sun H, Yan X, Li F, Li H, Fang H, Ning N, Cui Y, Han L. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax. 2012;67(7):632\u20138. https:\/\/doi.org\/10.1136\/thoraxjnl-2011-200018.","journal-title":"Thorax"},{"key":"7598_CR38","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.10826","author":"A Saifullah","year":"2021","unstructured":"Saifullah A, Mallhi TH, Khan YH, Iqbal MS, Alotaibi NH, Alzarea AI, Rasheed M. Evaluation of risk factors associated with the development of MDR- and XDR-TB in a tertiary care hospital: a retrospective cohort study. PeerJ. 2021. https:\/\/doi.org\/10.7717\/peerj.10826.","journal-title":"PeerJ"},{"issue":"8","key":"7598_CR39","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/thx.2006.065409","volume":"62","author":"A Story","year":"2007","unstructured":"Story A, Murad S, Roberts W, Verheyen M, Hayward AC, London Tuberculosis Nurses Network. Tuberculosis in London: the importance of homelessness, problem drug use and prison. Thorax. 2007;62(8):667\u201371. https:\/\/doi.org\/10.1136\/thx.2006.065409.","journal-title":"Thorax"},{"key":"7598_CR40","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.2147\/RMHP.S314777","volume":"14","author":"EM Woldesemayat","year":"2021","unstructured":"Woldesemayat EM. Tuberculosis in migrants is among the challenges of tuberculosis control in high-income countries. Risk Manag Healthc Policy. 2021;14:2965\u201370. https:\/\/doi.org\/10.2147\/RMHP.S314777.","journal-title":"Risk Manag Healthc Policy"},{"issue":"6","key":"7598_CR41","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01459740.2013.877900","volume":"33","author":"N Bartlett","year":"2014","unstructured":"Bartlett N, Garriott W, Raikhel E. What\u2019s in the \u201ctreatment gap\u201d? Ethnographic perspectives on addiction and global mental health from China, Russia, and the United States. Med Anthropol. 2014;33(6):457\u201377. https:\/\/doi.org\/10.1080\/01459740.2013.877900.","journal-title":"Med Anthropol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07598-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07598-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07598-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T16:08:30Z","timestamp":1657728510000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07598-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7598"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07598-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"assertion":[{"value":"1 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The informed consents were accepted and signed by all participants and legal guardians of the underage participants of the study. All methods used in the study were performed in accordance with the relevant guidelines and regulations. The Ethics Committees of Harbin Medical University (committee\u2019s reference number: KY2017-269) and Far Eastern State Medical University (committee\u2019s reference number: not applicable) approved the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, as no identifiable information of the participants was revealed in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"612"}}